Compare STRIDES PHARMA SCIENCE with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs PFIZER - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE PFIZER STRIDES PHARMA SCIENCE/
PFIZER
 
P/E (TTM) x 8.2 36.3 22.5% View Chart
P/BV x 1.0 6.1 15.9% View Chart
Dividend Yield % 0.5 0.6 89.2%  

Financials

 STRIDES PHARMA SCIENCE   PFIZER
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
PFIZER
Mar-19
STRIDES PHARMA SCIENCE/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,1473,840 29.9%   
Low Rs6422,080 30.9%   
Sales per share (Unadj.) Rs317.2455.0 69.7%  
Earnings per share (Unadj.) Rs7.893.8 8.4%  
Cash flow per share (Unadj.) Rs25.1109.4 22.9%  
Dividends per share (Unadj.) Rs2.0022.50 8.9%  
Dividend yield (eoy) %0.20.8 29.4%  
Book value per share (Unadj.) Rs274.3658.2 41.7%  
Shares outstanding (eoy) m89.5045.75 195.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.86.5 43.3%   
Avg P/E ratio x114.031.6 361.3%  
P/CF ratio (eoy) x35.727.1 131.9%  
Price / Book Value ratio x3.34.5 72.5%  
Dividend payout %25.524.0 106.3%   
Avg Mkt Cap Rs m80,058135,420 59.1%   
No. of employees `0002.52.6 95.3%   
Total wages/salary Rs m4,3413,238 134.0%   
Avg. sales/employee Rs Th11,325.87,911.4 143.2%   
Avg. wages/employee Rs Th1,731.41,230.9 140.7%   
Avg. net profit/employee Rs Th280.11,630.7 17.2%   
INCOME DATA
Net Sales Rs m28,39420,815 136.4%  
Other income Rs m9411,674 56.2%   
Total revenues Rs m29,33422,489 130.4%   
Gross profit Rs m3,9655,712 69.4%  
Depreciation Rs m1,540714 215.8%   
Interest Rs m1,96273 2,691.9%   
Profit before tax Rs m1,4036,599 21.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m972,309 4.2%   
Profit after tax Rs m7024,291 16.4%  
Gross profit margin %14.027.4 50.9%  
Effective tax rate %6.935.0 19.8%   
Net profit margin %2.520.6 12.0%  
BALANCE SHEET DATA
Current assets Rs m24,83627,167 91.4%   
Current liabilities Rs m18,9938,917 213.0%   
Net working cap to sales %20.687.7 23.5%  
Current ratio x1.33.0 42.9%  
Inventory Days Days7168 104.7%  
Debtors Days Days11330 376.7%  
Net fixed assets Rs m34,2898,862 386.9%   
Share capital Rs m895458 195.6%   
"Free" reserves Rs m23,65129,656 79.8%   
Net worth Rs m24,54630,113 81.5%   
Long term debt Rs m15,51325 62,052.8%   
Total assets Rs m65,43739,400 166.1%  
Interest coverage x1.791.5 1.9%   
Debt to equity ratio x0.60 76,128.5%  
Sales to assets ratio x0.40.5 82.1%   
Return on assets %4.111.1 36.8%  
Return on equity %2.914.2 20.1%  
Return on capital %6.922.1 31.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,697428 3,665.0%   
Fx outflow Rs m735786 93.5%   
Net fx Rs m14,962-358 -4,178.1%   
CASH FLOW
From Operations Rs m1,871978 191.3%  
From Investments Rs m5,826351 1,658.9%  
From Financial Activity Rs m-10,157-1,099 924.6%  
Net Cashflow Rs m-2,615231 -1,133.0%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 37.8 7.5 504.0%  
FIIs % 8.6 4.9 175.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 23.7 109.3%  
Shareholders   56,241 85,207 66.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   CIPLA  SANOFI INDIA  ALKEM LABORATORIES  ORCHID PHARMA LTD  NOVARTIS  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Why is Sensex at a Record High When Economy is in Trouble?(Podcast)

In today's episode, I talk about all the major moves of the week, including Modi government's blockbuster disinvestment, developments in the telecom sector.

Related Views on News

PFIZER at All Time High; BSE HEALTHCARE Index Up 0.7% (Market Updates)

Nov 22, 2019 | Updated on Nov 22, 2019

PFIZER share price has hit an all time high at Rs 4,199 (up 1.7%). The BSE HEALTHCARE Index is up by 0.7%. Among the top gainers in the BSE HEALTHCARE Index today are PFIZER (up 1.7%) and ABBOTT INDIA (up 0.6%). The top losers include DR. REDDYS LAB (down 0.1%) and ALKEM LABORATORIES (down 0.3%).

PFIZER at All Time High; BSE HEALTHCARE Index Up 0.3% (Market Updates)

Nov 22, 2019 | Updated on Nov 22, 2019

PFIZER share price has hit an all time high at Rs 4,189 (up 0.6%). The BSE HEALTHCARE Index is up by 0.3%. Among the top gainers in the BSE HEALTHCARE Index today are PFIZER (up 0.6%) and SANOFI INDIA (up 0.4%). The top losers include CADILA HEALTHCARE (down 0.1%) and GSK PHARMA (down 0.2%).

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

I Think Nestle, HUL, and Asian Paints Could Give Low Returns(Profit Hunter)

Nov 15, 2019

If you think high quality stocks will continue their dream run forever, then you must read this now.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Nov 22, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - SHASUN PHARMA COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS